Literature DB >> 11862566

Abdominoperineal resection for locally recurrent rectal cancer.

R Bergamaschi1, P Pessaux, P Burtin, J P Arnaud.   

Abstract

To evaluate whether surgical resection confers survival advantages in selected patients with resectable locally recurrent rectal cancer, data on 430 patients who underwent R0 resection for primary rectal cancer were prospectively collected over a 14-year period. Resection of recurrent disease was considered R0 when all cancer tissue was resected with microscopically tumor-free surgical margins. Microscopic evidence of disease at resection margins was considered an R1 resection. Recurrent disease was detected in 158 of 430 patients. Local recurrence was found in 91 patients, including (79%) with resection-site relapse only. These patients were considered for surgery unless defined unresectability criteria were met. A total of 35 patients who had abdominoperineal excision following anterior resection were studied retrospectively. Mortality associated with the procedure was 3% and morbidity was 20%. The resection was R0 in 12 patients, while microscopic margins were involved in 23 patients. 10 patients had extended resection of one or several adjacent organs Median operating time and blood loss were 250 min and 500 ml respectively. Median hospital stay was 25 days. 21/23 R1 patients received postoperative radiotherapy. Return to normal activity occurred at 8.2 (SD 4.2) weeks. No patients were lost to follow-up. Overall median survival was 26.4 months; 5-year survival was 25.4%. In spite of several survival predictors at univariate analysis, R0 or R1 resection was the only independent predictor of survival at multivariate analysis (add ratio 112.7, 95% CI 3.6-3500, p=0.007). Median survival rate was not reached at the 146-month follow-up in patients with R0 resection. Median survival rate was 16.6 months in patients with R1 resection. In conclusion, uninvolved microscopic margins produce long-term survivors after surgical resection for locally recurrent rectal cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11862566     DOI: 10.1007/pl00012131

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  5 in total

1.  Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP.

Authors:  Keiichi Jingu; Hisanori Ariga; Tomohiro Kaneta; Yoshihiro Takai; Ken Takeda; Lindel Katja; Kakutaro Narazaki; Takahiro Metoki; Keisuke Fujimoto; Rei Umezawa; Yoshihiro Ogawa; Kenji Nemoto; Masashi Koto; Masatoshi Mitsuya; Naruhiro Matsufuji; Shoki Takahashi; Shogo Yamada
Journal:  BMC Cancer       Date:  2010-04-07       Impact factor: 4.430

2.  Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003.

Authors:  Antonio Chiappa; Roberto Biffi; Andrew P Zbar; Fabrizio Luca; Cristiano Crotti; Emilio Bertani; Francesca Biella; Giulia Zampino; Roberto Orecchia; Nicola Fazio; Marco Venturino; Cristiano Crosta; Gian Carlo Pruneri; Carmine Grassi; Bruno Andreoni
Journal:  Int J Colorectal Dis       Date:  2004-12-16       Impact factor: 2.571

Review 3.  Intentionally curative treatment of locally recurrent rectal cancer: a systematic review.

Authors:  Pieter J Tanis; Annemiek Doeksen; J Jan B van Lanschot
Journal:  Can J Surg       Date:  2013-04       Impact factor: 2.089

4.  Sphincter-preserving surgery for recurrent pelvic malignancy using a hybrid procedure of open laparotomy and transanal endoscopic approach.

Authors:  Seiji Ishiguro; Shunichiro Komatsu; Kenichi Komaya; Takuya Saito; Takashi Arikawa; Kenichiro Kaneko; Tsuyoshi Sano
Journal:  Surg Case Rep       Date:  2018-04-12

5.  Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer.

Authors:  Raphaëla C Dresen; Marleen J Gosens; Hendrik Martijn; Grard A Nieuwenhuijzen; Geert-Jan Creemers; Alette W Daniels-Gooszen; Adriaan J van den Brule; Hetty A van den Berg; Harm J Rutten
Journal:  Ann Surg Oncol       Date:  2008-04-04       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.